FluMist can be used for protection against influenza virus subtypes A and B in individuals aged 2-49 years
The USFDA has given its approval to the first self administered nasal spray flu vaccine. FluMist can be used for protection against influenza virus subtypes A and B in individuals aged 2-49 years.
It is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a health care provider such as a doctor or a nurse or a field health worker. “Today’s approval of the first influenza vaccine for self- or caregiver-administration provides a new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience, flexibility and accessibility for individuals and families,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.
He added: “Getting vaccinated each year is the best way to prevent influenza, which causes illness in a substantial proportion of the U.S. population every year and may result in serious complications, including hospitalization and death. This approval adds another option for vaccination against influenza disease and demonstrates the FDA’s commitment to advancing public health”.
FluMist has been associated with low grade fever in young children post administration and runny nose or nasal congestion in adults. The vaccine contains a weakened form of live influenza virus strains. Though it can be administered by oneself or by a caregiver at home, a prescription is still required to buy it. It will be made available through online pharmacies.
